The central hypothesis is that use of mIVAA (mobile Inspección Visual con Ácido Acético - Spanish for Visual Inspection with Acetic Acid (VIA)) will increase the proportion of VIA positive women who complete follow-up clinical evaluation compared to VIA positive women in situations in which mIVAA was not used, thus potentially improving cervical cancer treatment and survival rates. The study will collect qualitative and quantitative data to examine the feasibility and preliminary impact of mIVAA on reducing attrition for follow-up clinical evaluations.
The study will be conducted in Lima, Peru in the context of mobile units operated by La Liga for promoting cancer screening. mIVAA comprises two components: a digital imaging device and a telemedicine platform. 1. The digital imaging device is either a mobile phone camera or the pocket colposcope plugged into a mobile phone. 2. The telemedicine platform is mobile phone-based, with an interface for midwives in the mobile units to enter patient information and acquire and upload cervical images, and an interface for the colposcopists based remotely to review the cervical images and patient information and return feedback. The specific aim is to pilot test mIVAA in a community-based setting in Peru.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
112
The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix
A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
La Liga Contra el Cancer-Peru
Lima, Peru
Percentage of Women Referred to a Follow up Screening Appointment With a Colposcopist Who Did Not Attend the Appointment
Time frame: up to 142 days
Percentage of Women Approached Who Consented to Participate in Study
Time frame: up to 142 days
Percentage of Women Approached Who Refused to Participate in Study
Time frame: up to 142 days
Number of Visual Inspection With Acetic Acid (VIA) Screened Women Who Are VIA+
Women who screened positive (i.e., suspicious) for cervical cancer/pre-cancer.
Time frame: up to 142 days
Average Number of Days From Screening to When a Follow up Appointment is Scheduled
Time frame: up to 142 days
Median Number of Days From Screening to When a Follow up Appointment is Scheduled
Time frame: up to 142 days
Percentage of Women Who Were Screened Using mIVAA
Time frame: up to 142 days
Average Number of Hours From Screening to When Expert Enters Feedback Using mIVAA
Time frame: up to 142 days
Percentage of mIVAA Screened Women With Expert Feedback Within 0-7 Days of mIVAA Screening Date
Time frame: up to 7 days
Number of Women Screened Positive (i.e., Suspicious) for Cervical Cancer/Pre-cancer by Midwife
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: up to 142 days
Number of Women Screened Positive (i.e., Suspicious) for Cervical Cancer/Pre-cancer by Expert Colposcopist
Time frame: up to 142 days
Average Number of Attempts Per Woman Before a Readable Image is Obtained by Midwife
Time frame: up to 142 days
Percentage of mIVAA Screened Women With at Least 1 Image Rated as Readable by Expert
Time frame: up to 142 days
Number of Instances of Network Failure
Time frame: up to 142 days